Metabolic syndrome and Cancer: Do they share common molecular pathways?

[1]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-1645.AlbertiKGEckelRHGrundySMZimmetPZCleemanJIDonatoKAFruchartJCJamesWPLoriaCMSmithSCJrHarmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of ObesityCirculation20091201640164510.1161/CIRCULATIONAHA.109.192644Search in Google Scholar

[2]Haslam DW, James WP. Obesity. Lancet 2005; 366:1197-1209.HaslamDWJamesWPObesityLancet20053661197120910.1016/S0140-6736(05)67483-1Search in Google Scholar

[3]Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, Ferlay J, Miranda JJ, Romieu I, Dikshit R, Forman D, Soerjomataram J. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 2015; 16:36-46.ArnoldMPandeyaNByrnesGRenehanAGStevensGAEzzatiMFerlayJMirandaJJRomieuIDikshitRFormanDSoerjomataramJGlobal burden of cancer attributable to high body-mass index in 2012: a population-based studyLancet Oncol201516364610.1016/S1470-2045(14)71123-4Search in Google Scholar

[4]Bhaskaran K, Douglas I, Forbes H et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014; 384(9945):755-765.BhaskaranKDouglasIForbesHet al.Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adultsLancet2014384994575576510.1016/S0140-6736(14)60892-8Search in Google Scholar

[5]Renehan AG, Tyson M, Egger M, Heller RF, Zawhlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569–578.RenehanAGTysonMEggerMHellerRFZawhlenM.Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesLancet200837156957810.1016/S0140-6736(08)60269-XSearch in Google Scholar

[6]Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 2010; 47:87–95.NicolucciA.Epidemiological aspects of neoplasms in diabetesActa Diabetol201047879510.1007/s00592-010-0187-3Search in Google Scholar

[7]Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010; 55:2846–2854.JafriHAlsheikh-AliAAKarasRHBaseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapyJ Am Coll Cardiol2010552846285410.1016/j.jacc.2009.12.069Search in Google Scholar

[8]Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation. 2002; 106: 3143-3421.Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)Final reportCirculation20021063143342110.1161/circ.106.25.3143Search in Google Scholar

[9]World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization; 1999.World Health OrganizationDefinition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO ConsultationPart 1: diagnosis and classification of diabetes mellitusGeneva, SwitzerlandWorld Health Organization1999Search in Google Scholar

[10]Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366:1059-1062.AlbertiKGZimmetPShawJ.IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definitionLancet20053661059106210.1016/S0140-6736(05)67402-8Search in Google Scholar

[11]Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer. A systematic review and meta-analysis. Diabetes Care 2012; 35:2402-2411.EspositoKChiodiniPColaoALenziAGiuglianoD.Metabolic syndrome and risk of cancerA systematic review and meta-analysis. Diabetes Care2012352402241110.2337/dc12-0336347689423093685Search in Google Scholar

[12]Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol 2006; 169:1505-1522.CoweySHardyRW.The metabolic syndrome: A high-risk state for cancer?Am J Pathol20061691505152210.2353/ajpath.2006.051090178022017071576Search in Google Scholar

[13]Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci 2011; 7:1003-1015.BraunSBitton-WormsKLeRoithD.The link between the metabolic syndrome and cancerInt J Biol Sci201171003101510.7150/ijbs.7.1003316415021912508Search in Google Scholar

[14]Fujihara S, Mori H, Kobara H, Nishiyama N, Kobayashi M, Oryu M, Masaki T. Metabolic syndrome, obesity, and gastrointestinal cancer. Gastroenterol Res Pract. 2012 (2012), Article ID 483623FujiharaSMoriHKobaraHNishiyamaNKobayashiMOryuMMasakiT.Metabolic syndrome, obesity, and gastrointestinal cancerGastroenterol Res Pract2012(2012), Article ID 48362310.1155/2012/483623353023223304125Search in Google Scholar

[15]Extermann M. Metabolic syndrome and cancer: From bedside to bench and back. Interdiscipl Top Gerontol 2013; 38:49-60.ExtermannM.Metabolic syndrome and cancer: From bedside to bench and backInterdiscipl Top Gerontol201338496010.1159/00034362123503515Search in Google Scholar

[16]Gallagher EJ, LeRoith D. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care 2013; 36(S2): S233-S239.GallagherEJLeRoithD.Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancerDiabetes Care201336S2S233S23910.2337/dcS13-2001392079423882051Search in Google Scholar

[17]Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and inflammation: new insights into breast cancer development and progression. ASCO Educational Book 2013: 46-51.IyengarNMHudisCADannenbergAJObesity and inflammation: new insights into breast cancer development and progressionASCO Educational Book2013465110.14694/EdBook_AM.2013.33.46389729923714453Search in Google Scholar

[18]Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25: 1476–1481.GovindarajanRRatnasingheLSimmonsDLSiegelERMidathadaMVKimLKimPJOwensRJLangNP.Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetesJ Clin Oncol2007251476148110.1200/JCO.2006.07.277717442990Search in Google Scholar

[19]Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 104(18): 1411-1421.MamtaniRHaynesKBilkerWBVaughnDJStromBLGlanzKLewisJD.Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort studyJ Natl Cancer Inst104181411142110.1093/jnci/djs328352959822878886Search in Google Scholar

[20]Colditz GA, Wolin KY, Gehlert S. Applying what we know to accelerate cancer prevention. Sci Transl Med 2012; 4(127): 127rv4.ColditzGAWolinKYGehlertS.Applying what we know to accelerate cancer preventionSci Transl Med20124127127rv410.1126/scitranslmed.3003218334363822461645Search in Google Scholar

[21]Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, Barry WT. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst 2015; 107(9): djv179doi: 10.1093/jnci/djv179.LigibelJACirrincioneCTLiuMCitronMIngleJNGradisharWMartinoSSikovWMichaelsonRMardisEPerouCMEllisMWinerEHudisCABerryDBarryWTBody Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)J Natl Cancer Inst20151079djv179doi10.1093/jnci/djv179465110626113580Open DOISearch in Google Scholar

[22]Peeters M, Price T, Cervantes A, Sobrero A, Ducreux MP, André T, Lordick F, Punt C, Koukakis R, Terwey J, Van Cutsem E. Impact of baseline covariates and prior therapy on the efficacy of second-line panitumumab (PMAB) + FOLFIRI vs FOLFIRI treatment. Ann Oncol 2014; 25(Suppl 4): iv187-188 (548P).PeetersMPriceTCervantesASobreroADucreuxMPAndréTLordickFPuntCKoukakisRTerweyJVan CutsemE.Impact of baseline covariates and prior therapy on the efficacy of second-line panitumumab (PMAB) + FOLFIRI vs FOLFIRI treatmentAnn Oncol201425Suppl 4iv187188(548P)10.1093/annonc/mdu333.50Search in Google Scholar

[23]Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, Fabian CJ, Gucalp A, Hershman DL, Hudson MM, Jones LW, Kakarala M, Ness KK, Merrill JK, Wollins DS, Hudis CA. American Society of Clinical Oncology Position Statement on Obesity and Cancer. J Clin Oncol 2014; 32: 3568-3574.LigibelJAAlfanoCMCourneyaKSDemark-WahnefriedWBurgerRAChlebowskiRTFabianCJGucalpAHershmanDLHudsonMMJonesLWKakaralaMNessKKMerrillJKWollinsDSHudisCA.American Society of Clinical Oncology Position Statement on Obesity and CancerJ Clin Oncol2014323568357410.1200/JCO.2014.58.4680497923725273035Search in Google Scholar